LAMEA Plasma Fractionation Market By Product (Immunoglobulins, Albumin, Coagulation factor VIII and Coagulation factor IX), By Sector (Private Sector and Public Sector), By Country, Growth Potential, Industry Analysis Report and Forecast, 2021 - 2027
Special Offering: Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support
Get in-depth analysis of the COVID-19 impact on the LAMEA Plasma Fractionation Market
Market Report Description
The Latin America, Middle East and Africa Plasma Fractionation Market would witness market growth of 10.3% CAGR during the forecast period (2021-2027). The plasma fractionation process is majorly dependent on various aspects like solubility of the products, and their physical & chemical conditions like ionic strengths, pH levels, and temperature, etc. the extracted plasma items, also called as Fresh Frozen Plasma (FFP) which are then subjected to several physical and mechanical treatments for virus inactivation like Chromatography centrifugation, detergent/solvent treatment, Nanofiltration, heat treatment, sterile filtration and ultrafiltration with an aim to attain homogeneity of plasma extracted from various donors and cut down the risks of viral transmissions.
The catalyst for the growth of the plasma fractionation market is the increasing geriatric population around the world, which is prone to several rare disorders that requires usage of plasma derivatives. In addition, the growth of the plasma fractionation market would be driven by the increasing utilization of immunoglobulins and alpha-1-antitrypsin in different medicine domain across the world. Moreover, the market growth is also supplemented by the increasing number of plasma collection centers across the world. Furthermore, supportive government initiatives to increase awareness regarding the usage of plasma-derived products are expected to propel the development of the overall plasma fractionation market.
The Private Sector market dominated the South Africa Plasma Fractionation Market by Sector in 2020, thereby, achieving a market value of $405.9 Million by 2027, growing at a CAGR of 10.6 % during the forecast period. The Public Sector market is expected to witness a CAGR of 11.8% during (2021 - 2027).
Based on Product, the market is segmented into Immunoglobulins, Albumin, Coagulation factor VIII and Coagulation factor IX. Based on Sector, the market is segmented into Private Sector and Public Sector. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Emergent BioSolutions, Inc., CSL Limited, Grifols S.A., Octapharma AG, Takeda Pharmaceutical Company Limited, Kedrion S.p.A, LFB S.A, Biotest AG (Tiancheng International Investment Limited), Sanquin Blood Supply Foundation, and Bio Products Laboratory Limited.
Scope of the Study
Market Segments Covered in the Report:
- Coagulation factor VIII
- Coagulation factor IX
- Private Sector
- Public Sector
- Saudi Arabia
- South Africa
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- Emergent BioSolutions, Inc.
- CSL Limited
- Grifols S.A.
- Octapharma AG
- Takeda Pharmaceutical Company Limited
- Kedrion S.p.A
- LFB S.A
- Biotest AG (Tiancheng International Investment Limited)
- Sanquin Blood Supply Foundation
- Bio Products Laboratory Limited
Unique Offerings from KBV Research
- Exhaustive coverage
- The highest number of market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free